Medesis Pharma

EHDN 2010

editeur — Wed, 18 Aug 2010 07:14:03 +0000

Medesis Pharma Successfully Completes Phase I Clinical Trial of NP01

editeur — Mon, 31 May 2010 14:31:08 +0000

The objective of this randomised, double blind, placebo controlled study was to evaluate the tolerability of NP01 in healthy male volunteers following single and repeat administration of 180ug of the drug’s active ingredient, vanadium.

The company reported that there were no serious adverse events and that the drug was well tolerated both after single and repeat administration.

“We are very pleased with the favorable results of this phase I trial” stated Jean-Claude Maurel, President and CEO of Medesis Pharma. “These results will not only allow us to move forward rapidly into our phase II trials, but also show clearly that our delivery technology used in other products in our pipeline, is also well tolerated.”

About NP01

NP01 is a combination of the active ingredient, vanadium, and Aonys®, a novel reverse micelle delivery formulation. Vanadium has unique metabolic regulation properties providing both glycemic control and mixed lipid homeostasis. The insulin sensitising properties of vanadium have been widely documented over the past 25 years, but traditional oral formulations of vanadium have failed to provide sufficient benefit at non-toxic doses. NP01 provides significant improvements in vanadium cellular bioavailability affording efficacy at vastly lower doses of the active ingredient.

About Type 2 Diabetes Mellitus

Type 2 diabetes mellitus is a metabolic disorder that is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency. By treating the underlying cause of type 2 diabetes; insulin resistance, long term glycemic control may be obtained.

About Medesis Pharma

Medesis Pharma is a clinical stage pharmaceutical company specialising in the development of a wide range of therapeutic agents based upon propriety Aonys® drug delivery technology. Aonys® is particularly applicable to metal and oligonucleotide active ingredients.

Contact

Peter Jackson PhD

Tel. +33 (0)4 67 10 71 61

Fax. +33 (0)4 67 72 26 21

EPIC Biotech

editeur — Thu, 27 May 2010 19:42:40 +0000

More details concerning this meeting can be found here

SMi 5th Conference on RNAi, siRNA and miRNA – The future of personalised medicine

editeur — Thu, 18 Mar 2010 08:56:01 +0000

More details of the meeting can be found here

3rd DIA Oligonucleotide-based Therapeutics Conference

editeur — Wed, 03 Mar 2010 13:39:14 +0000

On Wednesday 24th March, Medesis will present the latest developments in the use of Aonys® for systemic delivery of oligonucleotides in a talk entitled "Pharmaceutical Development of a Novel Oligonucleotide Delivery Formulation" More information on the 3rd DIA Oligonucleotide-based Therapeutics Conference: “Where Regulators and Industry Partner to Advance Oligonucleotide Science Together”, can be found here

2èmes rencontres Euro-Régionales de la biotechnologie et de la santé

editeur — Thu, 18 Feb 2010 09:11:46 +0000

Medesis Pharma will participate in the 2èmes rencontres Euro-Régionales de la biotechnologie et de la santé. More information can be found here

Letter to patients suffering from Huntington’s disease

editeur — Fri, 11 Dec 2009 14:52:38 +0000

On 5th November 2009, Medesis Pharma received a positive opinion from the Committee for Orphan Medicinal Products (COMP) for an orphan drug designation for the following product:

Lithium citrate tetrahydrate (in reverse-micelle formulation) for the treatment of Huntington’s disease......

Positive Opinion for Orphan Drug Designation

editeur — Thu, 03 Dec 2009 17:26:09 +0000

Medesis Pharma's treatment for Huntington's disease has received a positive opinion for orphan drug designation from the Committee for Ophan Medicinal Products (COMP). Lithium citrate tetrahydrate (in reverse-micelle formulation) for treatment of Huntington's disease (NP03) fulfilled the requirements for orphan drug designation based upon the level of prevalence of the disease in the European Community, and on the medical plausibility data based upon studies in a relevant transgenic mouse model. The neuroprotective activity shown in the mouse model at low doses of lithium, highlighted the unique delivery properties of the reverse micelle formulation, Aonys®, for lithium and other metals

XXIVièmes Journées Scientifiques du GTRV

editeur — Mon, 14 Sep 2009 14:16:34 +0000

For more information on this meeting please click here

EuroBioMed Colloque Maladies Rares et Ophelines

editeur — Sat, 29 Aug 2009 14:23:16 +0000

For more information on this meeting click here